Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 1
Submit an article Journal homepage
500
Views
14
CrossRef citations to date
0
Altmetric
Letter to the Editor

Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function*

Jillian R. GuntherDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Chanhyun ParkVanderbilt University, Nashville, TN, USA; View further author information
,
Bouthaina S. DabajaDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Sarah A. MilgromDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Ruben J. Cruz ChamorroPonce Health Sciences University, Ponce, Puerto Rico; ORCID Iconhttp://orcid.org/0000-0001-8410-7726View further author information
ORCID Icon,
L. Jeffrey MedeirosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Joseph D. KhouryDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Naveen GargDepartment of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Behrang AminiDepartment of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Raphael SteinerDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttp://orcid.org/0000-0003-3717-3629View further author information
ORCID Icon,
Ranjit NairDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Paolo StratiDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Jason R. WestinDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Hun Ju LeeDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Nathan FowlerDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttp://orcid.org/0000-0002-9494-1877View further author information
ORCID Icon,
Loretta NastoupilDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Sattva S. NeelapuDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
&
Chelsea C. PinnixDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-3982-3664View further author information
ORCID Icon show all
Pages 171-175 | Received 24 May 2019, Accepted 08 Jul 2019, Published online: 02 Aug 2019

References

  • Schreuder MI, van den Brand M, Hebeda KM, et al. Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma. J Hematopathol. 2017;10:91–107.
  • Teckie S, Qi S, Lovie S, et al. Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent. Int J Radiat Oncol Biol Phys. 2015;92:130–137.
  • Hoskin PJ, Kirkwood AA, Popova B, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014;15:457–463.
  • Konig L, et al. Response rates and recurrence patterns after low-dose radiotherapy with 4Gy in patients with low-grade lymphomas. Strahlenther Onkol. 2018;194:454–461.
  • Ganem G, Lambin P, Socié G, et al. Potential role for low dose limited-field radiation therapy (2 x 2 grays) in advanced low-grade non-Hodgkin’s lymphomas. Hematol Oncol. 1994;12:1–8.
  • Rodrigues NA, Killion L, Hickey G, et al. A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation. Int J Radiat Oncol Biol Phys. 2009;75:1079–1083.
  • Teckie S, Qi S, Chelius M, et al. Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma. Ann Oncol. 2017;28:1064–1069.
  • Jackson AE, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a multicenter, international experience of 248 patients (IELSG 41). Oncologist. 2015;20:1149–1153.
  • Anacak Y, Miller RC, Constantinou N, et al. Primary mucosa-associated lymphoid tissue lymphoma of the salivary glands: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys. 2012;82:315–320.
  • Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100:86–92.
  • Chan EK, Fung S, Gospodarowicz M, et al. Palliation by low-dose local radiation therapy for indolent non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2011;81:e781–6.
  • Haas RLM, Poortmans P, de Jong D, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003;21:2474–2480.
  • Girinsky T, Guillot-Vals D, Koscielny S, et al. A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. Int J Radiat Oncol Biol Phys. 2001;51:148–155.
  • Russo AL, Chen Y-H, Martin NE, et al. Low-dose involved-field radiation in the treatment of non-hodgkin lymphoma: predictors of response and treatment failure. Int J Radiat Oncol Biol Phys. 2013;86:121–127.
  • Pinnix CC, Dabaja BS, Milgrom SA, et al. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2017;39:1095–1100.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.